Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Nuclear Medicine Insights in PET, Theragnostic and Artificial Intelligence Applications
share announcement

Nuclear Medicine Insights in PET, Theragnostic and Artificial Intelligence Applications

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Radiobiology and Nuclear Medicine".

Deadline for manuscript submissions: closed (19 May 2023) | Viewed by 5153

Special Issue Editors

Dr. Riccardo Laudicella

E-Mail Website
Guest Editor
Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy
Interests: PET/CT; PET/MRI; artificial intelligence; theranostic
Special Issues, Collections and Topics in MDPI journals
Dr. Lucia Baratto

E-Mail Website
Guest Editor
Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA
Interests: pediatric molecular imaging; PET imaging; diagnostic imaging

Special Issue Information

Dear Colleagues,

New tracers (PSMA, FES, FAPI, and so on), advanced and innovative positron emission tomography (PET) technology, such as PET/MRI, improved detectors, and software technology are now available, enhancing PET applications and reducing radiotracer`s dose and scanning time. Additionally, in recent decades, several steps have been accomplished in the nuclear medicine therapy scenario (especially for theragnostic applications) with wider applications, approval, and reduced side effects, towards precision medicine. Both diagnostic (PET) and therapeutic applications of nuclear medicine can be magnified by artificial intelligence approaches.

This Special Issue aims to summarize the most promising technical and clinical applications/improvements in PET imaging and nuclear medicine therapy, with case reports, original papers, and reviews. To enhance the acceptance of molecular imaging diagnosis and therapy, new promising applications of artificial intelligence shall be presented: it is fundamental to deliver (and confirm) more evidence in the literature to further accelerate the use of artificial intelligence applications as well as the diffusion of new diagnostic and therapeutic approaches.

In this Special Issue, we will collect case reports, original articles, and reviews focused on novel insights in PET and nuclear medicine therapy, covering innovative applications, new radiopharmaceuticals, and technological improvements.

Dr. Riccardo Laudicella
Dr. Lucia Baratto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • theragnostic
  • artificial intelligence

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 2350 KiB  
Article
Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
by Stephan Skawran, Michael Messerli, Fotis Kotasidis, Josephine Trinckauf, Corina Weyermann, Ken Kudura, Daniela A. Ferraro, Janique Pitteloud, Valerie Treyer, Alexander Maurer, Martin W. Huellner and Irene A. Burger
Life 2022, 12(9), 1350; https://doi.org/10.3390/life12091350 - 30 Aug 2022
Cited by 5 | Viewed by 2907
Abstract
Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [18F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesions. Methods: Twenty-four patients were [...] Read more.
Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [18F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesions. Methods: Twenty-four patients were prospectively included to undergo dynamic WB [18F]FDG PET/CT for clinically indicated re-/staging of oncological diseases. Parametric maps of Ki and Vd were generated using Patlak analysis alongside SUV images. Maximum parameter values (SUVmax, Kimax, and Vdmax) were measured in liver parenchyma and in malignant or inflammatory/infectious lesions. Lesion-to-background ratios (LBRs) were calculated by dividing the measurements by their respective mean in the liver tissue. Results: Seventy-seven clinical target lesions were identified, 60 malignant and 17 inflammatory/infectious. Kimax was significantly higher in cancer than in inflammatory/infections lesions (3.0 vs. 2.0, p = 0.002) while LBRs of SUVmax, Kimax, and Vdmax did not differ significantly between the etiologies: LBR (SUVmax) 3.3 vs. 2.9, p = 0.06; LBR (Kimax) 5.0 vs. 4.4, p = 0.05, LBR (Vdmax) 1.1 vs. 1.0, p = 0.18). LBR of inflammatory/infectious and cancer lesions was higher in Kimax than in SUVmax (4.5 vs. 3.2, p < 0.001). LBRs of Kimax and SUVmax showed a strong correlation (Spearman’s rho = 0.83, p < 0.001). Conclusions: Dynamic WB [18F]FDG PET/CT is feasible in a clinical setting. LBRs of Kimax were higher than SUVmax. Kimax was higher in malignant than in inflammatory/infectious lesions but demonstrated a large overlap between the etiologies. Full article
(This article belongs to the Special Issue Nuclear Medicine Insights in PET, Theragnostic and Artificial Intelligence Applications)
►▼ Show Figures

Figure 1

Other

Jump to: Research

6 pages, 3591 KiB  
Case Report
Diagnostic Value of 2-[18F]FDG PET/CT in a Patient with Atypical Subacute Thyroiditis: A Case Report
by Teresa Kraus, Marcus Hacker, Werner Langsteger, Shuren Li and Raffaella Calabretta
Life 2022, 12(8), 1217; https://doi.org/10.3390/life12081217 - 10 Aug 2022
Cited by 1 | Viewed by 1218
Abstract
Background: Positron emission tomography/computed tomography (PET/CT) imaging with 2-deoxy-2-[18F]fluoro-d-glucose (2-[18F]FDG) is a sensitive diagnostic imaging modality in oncology and could be a useful diagnostic tool in patients with fever of unknown origin (FUO) or with inflammation of [...] Read more.
Background: Positron emission tomography/computed tomography (PET/CT) imaging with 2-deoxy-2-[18F]fluoro-d-glucose (2-[18F]FDG) is a sensitive diagnostic imaging modality in oncology and could be a useful diagnostic tool in patients with fever of unknown origin (FUO) or with inflammation of unknown origin (IUO). Case presentation: We report a case of a patient originally presenting with a clinical history of FUO and later with persistent high-sensitivity C-reactive protein (hsCRP) levels, even after antibiotic therapy. The patient underwent 2-[18F]FDG PET/CT to investigate and to localize a possible focus of infection or inflammation. 2-[18F]FDG hotspots were detected in both thyroid lobes. Thyroid diagnostic examinations and follow up were performed. Subacute thyroiditis (SAT) was then diagnosed by thyroid examinations, and other possible causes of FUO or IUO were not found. Conclusion: This case illustrates the potential diagnostic value of 2-[18F]FDG PET/CT in patients with atypical SAT, who originally present with only a clinical history of FUO. Full article
(This article belongs to the Special Issue Nuclear Medicine Insights in PET, Theragnostic and Artificial Intelligence Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop